Integra LifeSciences vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Integra LifeSciences Holdings (IART)

Q3 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

August 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Latest15 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.